BET inhibitors drive Natural Killer activation in non-small cell lung cancer via BRD4 and SMAD3

Abstract Non-small-cell lung carcinoma (NSCLC) is the most common lung cancer and one of the pioneer tumors in which immunotherapy has radically changed patients’ outcomes. However, several issues are emerging and their implementation is required to optimize immunotherapy-based protocols. In this wo...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Francesca Reggiani, Giovanna Talarico, Giulia Gobbi, Elisabetta Sauta, Federica Torricelli, Veronica Manicardi, Eleonora Zanetti, Stefania Orecchioni, Paolo Falvo, Simonetta Piana, Filippo Lococo, Massimiliano Paci, Francesco Bertolini, Alessia Ciarrocchi, Valentina Sancisi
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2024-03-01
Serie:	Nature Communications
Accesso online:	https://doi.org/10.1038/s41467-024-46778-8
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!